Alessia Fraccaroli
Overview
Explore the profile of Alessia Fraccaroli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fraccaroli A, Jurinovic V, Hirschbuhl K, Elena S, Koch K, Breitkopf S, et al.
Blood Adv
. 2025 Feb;
PMID: 39903105
Whether patients with acute myeloid leukemia (AML) harboring Nucleophosmin mutations (NPM1mut) with measurable residual disease (MRD) should undergo allogeneic stem cell transplantation (alloSCT) in complete remission (CR) remains subject of...
2.
Fraccaroli A, Stauffer E, Haebe S, Prevalsek D, Weiss L, Dorman K, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199629
Relapse and regimen-related toxicities remain major challenges in achieving long-term survival, particularly among older patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell...
3.
Fraccaroli A, Barnikel M, Scheubeck G, Buchstab O, Kunz W, Adolph L, et al.
Anticancer Res
. 2024 Aug;
44(9):4127-4132.
PMID: 39197917
Background: Acute liver failure (ALF) secondary to metastatic melanoma presents a rare and diagnostically challenging clinical scenario. Case Report: We report the case of a 57-year-old male who succumbed to...
4.
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kroger N, et al.
Blood
. 2024 Jul;
144(14):1532-1542.
PMID: 39007722
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy...
5.
Schulz F, Jager P, Tischer J, Fraccaroli A, Bug G, Hausmann A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339283
Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with...
6.
Haebe S, Fraccaroli A, Stauffer E, Prevalsek D, Zoellner A, Drolle H, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958420
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has demonstrated its potential as a curative option for patients with r/r lymphoma. With the introduction of post-transplant cyclophosphamide-based (PTCY) graft-versus-host disease (GvHD) prophylaxis,...
7.
Fraccaroli A, Vogt D, Rothmayer M, Spiekermann K, Pastore F, Tischer J
Ann Hematol
. 2023 Jun;
102(8):2213-2223.
PMID: 37300568
We sought to evaluate the role of extramedullary disease (EMD) in sequential RIC retrospectively analyzing data of 144 high-risk AML patients undergoing HLA-matched transplantation. Median long-term follow-up was 11.6 years....
8.
Fraccaroli A, Stauffer E, von Bergwelt-Baildon M, Tischer J
Dtsch Med Wochenschr
. 2023 Mar;
148(8):459-466.
PMID: 36990118
To date allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective immunotherapeutic approach for the treatment of acute myeloid leukemia (AML). It involves the transplantation of blood stem cells...
9.
Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D, et al.
Transplant Cell Ther
. 2022 Aug;
28(11):773.e1-773.e8.
PMID: 36031079
Baseline cytogenetics and disease status are key factors predicting the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The importance of cytogenetic risk in...
10.
Barnikel M, Alig A, Anton S, Arenz L, Bendz H, Fraccaroli A, et al.
PLoS One
. 2022 Jul;
17(7):e0271411.
PMID: 35834575
Objectives: Point-of-care lung ultrasound (LU) is an established tool in the first assessment of patients with coronavirus disease (COVID-19). To assess the progression or regression of respiratory failure in critically...